Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
Adrenergic beta-2 Receptor Agonists
/ administration & dosage
Bronchodilator Agents
/ administration & dosage
Drug Combinations
Glucocorticoids
/ administration & dosage
Humans
Muscarinic Antagonists
/ administration & dosage
Network Meta-Analysis
Pulmonary Disease, Chronic Obstructive
/ drug therapy
Randomized Controlled Trials as Topic
Severity of Illness Index
Chronic obstructive pulmonary disease
Exacerbation
Inhaled corticosteroid
Long-acting muscarinic antagonist
Long-acting β(2) agonist
Network meta-analysis
Trough forced expiratory volume in 1 s
Journal
Pulmonary pharmacology & therapeutics
ISSN: 1522-9629
Titre abrégé: Pulm Pharmacol Ther
Pays: England
ID NLM: 9715279
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
03
07
2019
revised:
14
10
2019
accepted:
14
10
2019
pubmed:
23
10
2019
medline:
4
9
2020
entrez:
23
10
2019
Statut:
ppublish
Résumé
Inhaled corticosteroid (ICS)/long-acting β A network meta-analysis (≥3 nodes, Bayesian method) was performed by searching for randomized clinical trials (RCTs) that compared the impact of different LABA/LAMA FDCs vs. ICS/LABA FDCs on both primary and secondary endpoints. The primary endpoints were: the change from baseline in trough forced expiratory volume in 1 s (FEV Data of 17,734 COPD patients were extracted from 16 RCTs. The length of treatment ranged from 6 weeks to 52 weeks. All LABA/LAMA FDCs, except aclidinium/formoterol, produced a statistically significant improvement compared to ICS/LABAs in trough FEV The results of this meta-analysis show that LABA/LAMA combinations are consistently more effective than ICS/LABA FDCs for most of the evaluated outcomes. However, differences have also been observed between FDCs belonging to the same class. Across the investigated LABA/LAMA FDCs, glycopyrronium/indacaterol revealed a consistent and robust efficacy profile.
Sections du résumé
BACKGROUND
Inhaled corticosteroid (ICS)/long-acting β
METHODS
A network meta-analysis (≥3 nodes, Bayesian method) was performed by searching for randomized clinical trials (RCTs) that compared the impact of different LABA/LAMA FDCs vs. ICS/LABA FDCs on both primary and secondary endpoints. The primary endpoints were: the change from baseline in trough forced expiratory volume in 1 s (FEV
RESULTS
Data of 17,734 COPD patients were extracted from 16 RCTs. The length of treatment ranged from 6 weeks to 52 weeks. All LABA/LAMA FDCs, except aclidinium/formoterol, produced a statistically significant improvement compared to ICS/LABAs in trough FEV
CONCLUSIONS
The results of this meta-analysis show that LABA/LAMA combinations are consistently more effective than ICS/LABA FDCs for most of the evaluated outcomes. However, differences have also been observed between FDCs belonging to the same class. Across the investigated LABA/LAMA FDCs, glycopyrronium/indacaterol revealed a consistent and robust efficacy profile.
Identifiants
pubmed: 31639476
pii: S1094-5539(19)30162-2
doi: 10.1016/j.pupt.2019.101855
pii:
doi:
Substances chimiques
Adrenergic beta-2 Receptor Agonists
0
Bronchodilator Agents
0
Drug Combinations
0
Glucocorticoids
0
Muscarinic Antagonists
0
Types de publication
Comparative Study
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101855Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.